{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:33:35Z","timestamp":1791686015194,"version":"4.3.4"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Unlike younger adults with acute lymphoblastic leukemia (ALL), older adults are rarely cured due to a combination of intrinsic disease resistance and treatment-related toxicities. Novel therapeutics such as inotuzumab ozogamicin, blinatumomab, venetoclax, and ABL kinase inhibitors have high activity in ALL and are well tolerated by older adults. Frontline treatment regimens for older adults using novel therapeutics with reduction or omission of conventional chemotherapy are being developed with early results demonstrating high remission rates and lower toxicity, but long-term efficacy and toxicity data are lacking. Collaboration between academic and pharmaceutical stakeholders is needed to develop clinical trials to define the optimal treatment regimens for older adults with ALL.<\/jats:p>","DOI":"10.1182\/hematology.2021000226","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:22:01Z","timestamp":1639138921000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?"],"prefix":"10.1182","volume":"2021","author":[{"given":"Marlise R.","family":"Luskin","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Department of Medical Oncology, Division of Leukemia, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"23","key":"2021121012092704200_hem2021000226C1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"issue":"27","key":"2021121012092704200_hem2021000226C2","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021121012092704200_hem2021000226C3","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: leukemia\u2014acute lymphocytic leukemia (ALL). 2020. Accessed 2July2021. https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html."},{"issue":"8","key":"2021121012092704200_hem2021000226C4","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"issue":"5","key":"2021121012092704200_hem2021000226C5","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"issue":"12","key":"2021121012092704200_hem2021000226C6","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"2021121012092704200_hem2021000226C7","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2021121012092704200_hem2021000226C8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"2021121012092704200_hem2021000226C9","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2021121012092704200_hem2021000226C10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","article-title":"Treatment of older patients with acute lymphoblastic leukemia","volume":"2016","author":"G\u00f6kbuget","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2021121012092704200_hem2021000226C11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"2021121012092704200_hem2021000226C12","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"issue":"15","key":"2021121012092704200_hem2021000226C13","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/cncr.30037","article-title":"Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia","volume":"122","author":"Fathi","year":"2016","journal-title":"Cancer"},{"issue":"21","key":"2021121012092704200_hem2021000226C14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood.V120.21.1493.1493","article-title":"Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL)","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2021121012092704200_hem2021000226C15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"2021121012092704200_hem2021000226C16","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2012-07-379016","article-title":"How I treat older patients with ALL","volume":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"key":"2021121012092704200_hem2021000226C17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2015.11.012","article-title":"Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group","volume":"41","author":"Ribera","year":"2016","journal-title":"Leuk Res"},{"issue":"6","key":"2021121012092704200_hem2021000226C18","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1080\/10428194.2018.1538505","article-title":"Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL","volume":"60","author":"Kim","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2021121012092704200_hem2021000226C19","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2021121012092704200_hem2021000226C20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2021121012092704200_hem2021000226C21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2021121012092704200_hem2021000226C22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C23","first-page":"1014","article-title":"Reduced-intensity chemotherapy with mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: results from a phase II study","volume":"136","author":"Short","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C24","first-page":"267","article-title":"First results of an open label phase II study to evaluate the efficacy and safety of inotuzumab ozogamicin for induction therapy followed by conventional chemotherapy based consolidation and maintenance therapy in patients aged 56 years and older with acute lymphoblastic leukemia (INITIAL-1 trial)","volume":"136","author":"Stelljes","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C25","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/blood-2019-129988","article-title":"A multicenter phase I study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed\/refractory acute lymphoblastic leukemia","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2018-99-111992","article-title":"Results of SWOG 1318: a phase 2 trial of blinatumomab followed by POMP (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed Philadelphia chromosome negative B-cell acute lymphoblastic leukemia","volume":"132","author":"Advani","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2021121012092704200_hem2021000226C27","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2019-126977","article-title":"Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed\/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"134","author":"Lacayo","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2021121012092704200_hem2021000226C29","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2021121012092704200_hem2021000226C30","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood.2020008544","article-title":"Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL","volume":"137","author":"Kirchhoff","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2021121012092704200_hem2021000226C31","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","article-title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2021121012092704200_hem2021000226C32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/hematology.2019000010","article-title":"Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant","volume":"2019","author":"Fielding","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2021121012092704200_hem2021000226C33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2018-08-832105","article-title":"How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"133","author":"Ravandi","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2021121012092704200_hem2021000226C34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/bjh.12043","article-title":"Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols","volume":"159","author":"Ribera","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2021121012092704200_hem2021000226C35","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2018-99-114552","article-title":"Nilotinib (Tasigna\u00ae) and low intensity chemotherapy for first-line treatment of elderly patients with BCR-ABL1-positive acute lymphoblastic leukemia: final results of a prospective multicenter trial (EWALL-PH02)","volume":"132","author":"Ottmann","year":"2018","journal-title":"Blood"},{"issue":"24","key":"2021121012092704200_hem2021000226C37","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2021121012092704200_hem2021000226C38","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","article-title":"Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"issue":"25","key":"2021121012092704200_hem2021000226C39","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V130.Suppl_1.99.99","article-title":"First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"130","author":"Martinelli","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2018-99-120029","article-title":"A phase II study of dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed Ph\/BCR-ABL-positive acute lymphoblastic leukemia (Ph+ ALL): final results Alliance\/CALGB study 10701","volume":"132","author":"Wieduwilt","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092704200_hem2021000226C42","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/blood-2019-125138","article-title":"A phase I study of asciminib (ABL001) in combination with dasatinib and prednisone for untreated BCR-ABL1-positive ALL in older adults","volume":"134","author":"Luskin","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2021121012092704200_hem2021000226C43","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2021121012092704200_hem2021000226C44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2019.1680839","article-title":"Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"61","author":"Derman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2021121012092704200_hem2021000226C45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjh.12561","article-title":"Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol","volume":"163","author":"Martell","year":"2013","journal-title":"Br J Haematol"},{"issue":"8","key":"2021121012092704200_hem2021000226C46","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ajh.24410","article-title":"Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission","volume":"91","author":"Wolach","year":"2016","journal-title":"Am J Hematol"},{"issue":"10","key":"2021121012092704200_hem2021000226C47","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021121012092704200_hem2021000226C48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jgo.2019.10.002","article-title":"Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: report of CALGB 361006 (Alliance)","volume":"11","author":"Klepin","year":"2020","journal-title":"J Geriatr Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/7\/1852080\/7luskin.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/7\/1852080\/7luskin.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:22:46Z","timestamp":1639138966000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/7\/482963\/Acute-lymphoblastic-leukemia-in-older-adults"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000226","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}